Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Comparison of clinical and biochemical parameters at baseline and 24 weeks

From: Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study

 

Semaglutide group

DPP-4 inhibitors group

 
 

Baseline

24 weeks

p1 value

Baseline

24 weeks

p1 value

p2 value

Body weight (kg)

67.9 ± 12.7

65.6 ± 12.8

0.353

65.1 ± 12.0

64.7 ± 12.0

0.899

 < 0.001*

Systolic blood pressure(mmHg)

131.5 ± 17.8

130.5 ± 20.1

0.862

130.6 ± 14.6

131.6 ± 18.1

0.818

0.683

Diastolic blood pressure(mmHg)

74.1 ± 11.3

75.4 ± 13.3

0.728

74.7 ± 11.3

73.8 ± 15.1

0.800

0.404

HDL-C (mg/dL)

55.2 ± 12.3

58.3 ± 12.5

0.395

56.7 ± 11.6

57.3 ± 12.5

0.866

0.133

LDL-C (mg/dL)

94.9 ± 16.2

94.8 ± 23.4

0.989

96.3 ± 20.8

96.6 ± 20.2

0.924

0.623

Triglyceride (mg/dL)

117.0

(93.5–205.0)

119.0

(91.3–168.8)

0.853

110.0

(83.0–183.0)

123.0

(88.0–227.0)

0.421

0.456

AST(GOT) (U/L)

20.5

(17.3–26.8)

20.5

(17.0–28.0)

0.910

19.0

(16.0–28.0)

22.0

(17.0–26.0)

0.516

0.208

ALT(GPT) (U/L)

24.0

(16.0–36.8)

20.5

(15.0–33.8)

0.680

21.0

(15.0–36.0)

21.0

(14.0–35.0)

0.723

0.082

γ-GTP (U/L)

28.0

(20.4–41.5)

27.5

(20.3–38.5)

0.781

29.0

(20.0–58.0)

29.0

(20.0–68.0)

0.723

0.119

eGFR (ml/min/1.73 m2)

74.2 ± 21.4

72.4 ± 18.3

0.766

69.7 ± 15.5

65.8 ± 18.8

0.413

0.623

UACR (mg/g Cre)

22.9

(10.6–53.9)

30.6

(9.4–74.3)

0.757

25.0

(8.6–47.1)

21.6

(11.8–42.7)

0.972

0.462

FPG (mg/dL)

144.6 ± 27.0

129.6 ± 23.9

0.047*

149.0 ± 24.7

151.7 ± 36.1

0.753

0.047*

HbA1c (%)

7.6 ± 0.4

7.1 ± 0.6

0.003*

7.6 ± 0.4

7.5 ± 0.6

0.921

0.001*

Mean glucose level (mg/dL)

157.1 ± 21.8

143.1 ± 26.4

0.051

159.4 ± 18.2

161.7 ± 22.7

0.690

0.006*

SD (mg/dL)

40.1 ± 6.9

35.8 ± 10.1

0.091

39.8 ± 8.5

41.7 ± 9.6

0.458

0.008*

MAGE (mg/dL)

105.4 ± 26.9

88.1 ± 26.3

0.029*

99.9 ± 20.8

105.5 ± 24.4

0.371

0.001*

MODD (mg/dL)

34.0 ± 7.8

30.2 ± 9.6

0.140

33.9 ± 8.0

35.5 ± 9.4

0.493

0.008*

%CV

25.9 ± 5.4

25.0 ± 5.6

0.572

25.0 ± 4.7

25.7 ± 4.8

0.577

0.099

Time above range (%)

28.3 ± 15.4

17.8 ± 17.6

0.033*

28.3 ± 14.1

29.7 ± 18.0

0.758

0.009*

Time in range (%)

70.6 ± 14.5

81.0 ± 17.2

0.028*

71.6 ± 14.1

70.1 ± 18.0

0.737

0.008*

Time below range (%)

0.0 (0.0–0.0)

0.0 (0.0–0.7)

0.945

0.0 (0.0–0.0)

0.0 (0.0–0.1)

0.203

0.780

d-ROMs (U.CARR)

348.5 ± 73.1

305.0 ± 52.4

0.022*

362.1 ± 93.8

356.7 ± 105.3

0.672

0.007*

  1. Data are expressed as mean ± standard deviation, medians (interquartile ranges), or numbers (%)
  2. p.1 value for the intragroup comparison (pre- vs post-treatment values in Semaglutide or DPP-4 inhibitors group, *:p < 0.05)
  3. p.2 value for the intergroup comparison (Semaglutide vs DPP-4 inhibitors group in the changes from pre- to post-treatment, *:p < 0.05)
  4. HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, eGFR Estimated glomerular filtration rate, FPG Fasting plasma glucose, HbA1c Hemoglobin A1c, SD Standard deviation, MAGE Mean amplitude of glycemic excursions, MODD Mean of daily difference of blood glucose, %CV Percentage coefficient of variation for glucose, d-ROMs Diacron-reactive oxygen metabolites
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us